Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists
This commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and demerits...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-08-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/16/4101 |
| _version_ | 1797585225810706432 |
|---|---|
| author | Wenxin Zheng |
| author_facet | Wenxin Zheng |
| author_sort | Wenxin Zheng |
| collection | DOAJ |
| description | This commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and demerits of its application to aggressive endometrial cancers. The commentary review sheds light on the recent introductions of lymphovascular space invasion (LVSI) and lymph node metastasis size in cancer staging. It outlines the difficulties in differentiating between synchronous and metastatic endometrial and ovarian cancers, underlining their implications on treatment strategies. Furthermore, the commentary discusses the integration of molecular classifications within the FIGO 2023 framework, emphasizing the pivotal yet challenging implementation of the pathogenic POLE mutation test. The commentary concludes by reaffirming the vital role of pathologists in executing the FIGO 2023 staging system. |
| first_indexed | 2024-03-11T00:03:03Z |
| format | Article |
| id | doaj.art-1fffe35ba663410386b889c4ac4fa012 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-11T00:03:03Z |
| publishDate | 2023-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-1fffe35ba663410386b889c4ac4fa0122023-11-19T00:33:15ZengMDPI AGCancers2072-66942023-08-011516410110.3390/cancers15164101Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for PathologistsWenxin Zheng0Department of Pathology, Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USAThis commentary explores the complexities of the FIGO 2023 staging system and the inclusion of The Cancer Genome Atlas’s (TCGA) molecular classification in the management of endometrial cancer. It highlights the importance of histology as a prognostic tool, while scrutinizing the merits and demerits of its application to aggressive endometrial cancers. The commentary review sheds light on the recent introductions of lymphovascular space invasion (LVSI) and lymph node metastasis size in cancer staging. It outlines the difficulties in differentiating between synchronous and metastatic endometrial and ovarian cancers, underlining their implications on treatment strategies. Furthermore, the commentary discusses the integration of molecular classifications within the FIGO 2023 framework, emphasizing the pivotal yet challenging implementation of the pathogenic POLE mutation test. The commentary concludes by reaffirming the vital role of pathologists in executing the FIGO 2023 staging system.https://www.mdpi.com/2072-6694/15/16/4101endometrial cancerFIGO stagingmolecular classificationTCGA-ECPOLE mutations |
| spellingShingle | Wenxin Zheng Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists Cancers endometrial cancer FIGO staging molecular classification TCGA-EC POLE mutations |
| title | Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists |
| title_full | Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists |
| title_fullStr | Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists |
| title_full_unstemmed | Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists |
| title_short | Molecular Classification of Endometrial Cancer and the 2023 FIGO Staging: Exploring the Challenges and Opportunities for Pathologists |
| title_sort | molecular classification of endometrial cancer and the 2023 figo staging exploring the challenges and opportunities for pathologists |
| topic | endometrial cancer FIGO staging molecular classification TCGA-EC POLE mutations |
| url | https://www.mdpi.com/2072-6694/15/16/4101 |
| work_keys_str_mv | AT wenxinzheng molecularclassificationofendometrialcancerandthe2023figostagingexploringthechallengesandopportunitiesforpathologists |